Literature DB >> 8099291

Systemic and local tolerability of ophthalmic drug formulations. An update.

F C Hugues1, C Le Jeunne.   

Abstract

All eye drops raise problems of local tolerance, but with variable frequencies. They can induce pain on instillation, allergic reactions, delayed healing, punctate keratitis, disturbances of lacrimal secretion, disturbances of accommodation (especially the parasympathomimetics) and local pigmentation after prolonged use. Corticosteroids are associated with 2 major risks: chronic glaucoma and cataract, initially reversible if treatment is stopped. There is still a major risk of corneal herpes with corticosteroids. It is important to be aware of these local problems as they are responsible for poor patient compliance. The systemic effects essentially concern the agonists and antagonists of the autonomic nervous system. beta-Blocker eye drops can cause bronchospasm, heart failure, syncope and psychiatric disorders, especially at high doses and with nonselective beta-blockers. These consequences are usually related to failure to comply with the prescribing precautions. alpha-Adrenergic agonists, which exert dose-dependent effects, can induce hypertensive crises or angina attacks. Apart from patients at risk (children under the age of 30 months and the elderly), parasympathomimetics cause few systemic adverse effects; anticholinesterases, which have curare-like properties, are contraindicated for 6 weeks before general anesthesia. In the very young and the very old, atropinic eye drops carry a risk of cardiovascular collapse and neuropsychiatric disturbances. Problems may also occur with other classes of drugs such as anti-infectives, antispectics, anti-inflammatories and contact lens products. Nevertheless, it is clear that this form of treatment is generally very well tolerated in relation to the volume of eye drops prescribed by ophthalmologists each day.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099291     DOI: 10.2165/00002018-199308050-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  103 in total

1.  [Asthma and betaxolol eye-wash].

Authors:  C Le Jeunne; Y Munera; F C Hugues
Journal:  Rev Mal Respir       Date:  1991       Impact factor: 0.622

2.  Hazards of unit dose artificial tear preparations.

Authors:  M Loeffler; A Hornblass
Journal:  Arch Ophthalmol       Date:  1990-05

3.  [Glaucoma].

Authors:  E Hachet
Journal:  Bull Soc Ophtalmol Fr       Date:  1985-11

4.  Hypertension following 10 per cent phenylephrine ophthalmic.

Authors:  D Solosko; R B Smith
Journal:  Anesthesiology       Date:  1972-02       Impact factor: 7.892

5.  [Drug-induced complications in ophthalmology].

Authors:  D A Lebuisson; J J Aron; J L Couderc
Journal:  Rev Prat       Date:  1982-01-01

6.  Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.

Authors:  F T Fraunfelder; G C Bagby; D J Kelly
Journal:  Am J Ophthalmol       Date:  1982-03       Impact factor: 5.258

7.  Effects of long-term treatment with timolol on lacrimal gland function.

Authors:  R L Coakes; I A Mackie; D V Seal
Journal:  Br J Ophthalmol       Date:  1981-09       Impact factor: 4.638

8.  Adverse reactions from timolol administration.

Authors:  E M Van Buskirk
Journal:  Ophthalmology       Date:  1980-05       Impact factor: 12.079

Review 9.  Systemic drug interactions with topical glaucoma medications.

Authors:  S L Gerber; L B Cantor; D C Brater
Journal:  Surv Ophthalmol       Date:  1990 Nov-Dec       Impact factor: 6.048

10.  Blindness from misuse of over-the-counter eye medications.

Authors:  M B Rumelt
Journal:  Ann Ophthalmol       Date:  1988-01
View more
  7 in total

1.  [Corneal wound healing. II. Treatment of disorders of wound healing].

Authors:  P W Rieck; U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

Review 2.  Corneal ulceration in pediatric patients: a brief overview of progress in topical treatment.

Authors:  Serina Stretton; Usha Gopinathan; Mark D P Willcox
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  Injectable drug depot engineered to release multiple ophthalmic therapeutic agents with precise time profiles for postoperative treatment following ocular surgery.

Authors:  Maziar Mohammadi; Kisha Patel; Seyedeh P Alaie; Ron B Shmueli; Cagri G Besirli; Ronald G Larson; Jordan J Green
Journal:  Acta Biomater       Date:  2018-04-21       Impact factor: 8.947

4.  Prophylactic effectiveness of tobramycin-dexamethasone eye drops compared with tobramycin/vehicle eye drops in controlling post-surgical inflammation in cataract patients : prospective, randomised, double-masked, two-arm, parallel-group, placebo-controlled, multicentre study.

Authors:  Ricardo Notivol; Dina Amin; Anna Whitling; David Wells; Margaret Kennedy; Paul C Cockrum
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

5.  Vision-related quality of life and symptom perception change over time in newly-diagnosed primary open angle glaucoma patients.

Authors:  Ivano Riva; Lorenzo Legramandi; Eliana Rulli; Anastasios G Konstas; Andreas Katsanos; Francesco Oddone; Robert N Weinreb; Luciano Quaranta
Journal:  Sci Rep       Date:  2019-05-01       Impact factor: 4.379

6.  Effect of Tratak (Yogic Ocular Exercises) on Intraocular Pressure in Glaucoma: An RCT.

Authors:  Tanuj Dada; Raj Kumar Yadav; Hanjabam Barun Sharma; Ritesh Kumar Netam; Kanwal Preet Kochhar
Journal:  Int J Yoga       Date:  2022-03-21

Review 7.  Quality of Life in Glaucoma: A Review of the Literature.

Authors:  Luciano Quaranta; Ivano Riva; Chiara Gerardi; Francesco Oddone; Irene Floriani; Anastasios G P Konstas
Journal:  Adv Ther       Date:  2016-04-30       Impact factor: 3.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.